

Georgia Ragia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3554999/publications.pdf>

Version: 2024-02-01

36
papers

825
citations

566801

15
h-index

500791

28
g-index

37
all docs

37
docs citations

37
times ranked

1277
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>MTHFR</i> c.665C>T guided fluoropyrimidine therapy in cancer: gender-dependent effect on dose requirements. <i>Drug Metabolism and Personalized Therapy</i> , 2022, 37, 323-327.	0.3	6
2	Gender-dependent association of <i>TYMS</i> - <i>TSER</i> polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity. <i>Pharmacogenomics</i> , 2021, 22, 669-680.	0.6	8
3	<i>TCF7L2</i> rs7903146 C>T gene polymorphism is not associated with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	1
4	Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1623-1630.	0.8	81
5	Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry. <i>Pharmacogenomics</i> , 2020, 21, 1311-1329.	0.6	28
6	Association study of the <i>CTH</i> 1364 G>T polymorphism with coronary artery disease in the Greek population. <i>Drug Metabolism and Personalized Therapy</i> , 2019, 34, .	0.3	5
7	Pharmacogenomics of anticoagulation therapy: the last 10 years. <i>Pharmacogenomics</i> , 2019, 20, 1113-1117.	0.6	7
8	Genetics of Obstructive Sleep Apnea: Vitamin D Receptor Gene Variation Affects Both Vitamin D Serum Concentration and Disease Susceptibility. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 45-53.	1.0	17
9	Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 226-233.	0.6	8
10	Metabolic Syndrome and Vitamin D Levels in Patients with Obstructive Sleep Apnea Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2018, 16, 190-196.	0.5	13
11	From Homer and Hippocrates to modern personalized medicine: is there a role for pharmacoepigenomics in the treatment of alcohol addiction?. <i>Pharmacogenomics</i> , 2018, 19, 513-516.	0.6	1
12	A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial. <i>Pharmacogenomics</i> , 2017, 18, 23-34.	0.6	10
13	Epigenetics-by-Sex Interaction for Coronary Artery Disease Risk Conferred by the Cystathionine β -Lyase Gene Promoter Methylation. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 741-748.	1.0	19
14	Role of <i>CYP4F2</i> , <i>CYP2C19</i> , and <i>CYP1A2</i> polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis. <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 183-190.	0.3	2
15	Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond. <i>Current Pharmaceutical Biotechnology</i> , 2017, 18, 221-230.	0.9	13
16	<i>CYP3A5</i> genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin. <i>Genetics and Molecular Biology</i> , 2015, 38, 129-137.	0.6	6
17	Gene-gene interaction of μ -opioid receptor and <i>Glur5</i> kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 129-135.	0.3	3
18	Frequency of <i>CYP450</i> enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 235-248.	0.3	12

#	ARTICLE	IF	CITATIONS
19	<i>POR</i> SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. <i>Pharmacogenomics</i> , 2014, 15, 1963-1972.	0.6	17
20	Lack of Association of the P450 Oxidoreductase *28 Single Nucleotide Polymorphism with the Lipid-Lowering Effect of Statins in Hypercholesterolemic Patients. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 323-31.	1.6	11
21	Pharmacogenomics of Oral Antidiabetic Drugs. , 2014, , 683-713.		2
22	Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin. <i>Open Cardiovascular Medicine Journal</i> , 2014, 8, 12-17.	0.6	8
23	Association of monocyte chemoattractant protein-1 $\sim 2518A \rightarrow G$ polymorphism with occurrence, severity, and outcome in ischemic stroke. <i>Neurological Sciences</i> , 2013, 34, 1315-1320.	0.9	8
24	Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia. <i>BioMed Research International</i> , 2013, 2013, 1-6.	0.9	25
25	Association of Functional VKORC1 Promoter Polymorphism with Occurrence and Clinical Aspects of Ischemic Stroke in a Greek Population. <i>Disease Markers</i> , 2013, 35, 641-646.	0.6	11
26	Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated Type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2012, 98, 119-124.	1.1	32
27	Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics. <i>Drug Metabolism and Drug Interactions</i> , 2012, 27, 19-31.	0.3	16
28	Research Highlights. <i>Pharmacogenomics</i> , 2012, 13, 261-264.	0.6	1
29	Association of VKORC1 $\sim 1639 G \rightarrow A$ polymorphism with carotid intima-media thickness in type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2011, 94, 236-241.	1.1	18
30	Pharmacogenomics of oral antidiabetic medications: current data and pharmacogenomic perspective. <i>Pharmacogenomics</i> , 2011, 12, 1161-1191.	0.6	65
31	Endothelial nitric oxide synthase gene polymorphisms -786T \rightarrow C and 894G \rightarrow T in coronary artery bypass graft surgery patients. <i>Human Genomics</i> , 2010, 4, 375.	1.4	28
32	Renin-angiotensin-aldosterone system gene polymorphisms in coronary artery bypass graft surgery patients. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2010, 11, 136-145.	1.0	16
33	Pharmacogenetics of coumarinic oral anticoagulants. <i>Pharmacogenomics</i> , 2010, 11, 493-496.	0.6	61
34	Need for reassessment of reported <i>CYP2C19</i> allele frequencies in various populations in view of <i>CYP2C19</i> *17 discovery: the case of Greece. <i>Pharmacogenomics</i> , 2009, 10, 43-49.	0.6	62
35	Presence of <i>CYP2C9</i> *3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. <i>Pharmacogenomics</i> , 2009, 10, 1781-1787.	0.6	84
36	Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 419-426.	1.0	106